CSL WELL-POSITIONED AFTER NEW US DEAL
Blood products supplier CSL Ltd has clinched a potentially lucrative new US
research deal and says its in good shape for the future as plasma prices stabilise.
The Melbourne company on Wednesday posted an annual net profit of $546.5 million
for 2004/05, more than double the $219.6 million result of the previous year.
Managing director Brian McNamee on Wednesday forecast growth in earnings before
interest, tax, depreciation and amortization (EBITDA) of 10 per cent this year
as the company was enters a new development phase.